Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study

Table 1 Description of the case population studied

	Gender	Age	Fertile	Heme arginate	PBG	ALA	GFR
F1	F	54	No	No	3	1	>60
F2	F	32	Yes	No	7	6	>60
F3	F	36	Yes	No	10	6	>60
F4	F	37	Yes	No	16	10	>60
F5	F	25	Yes	No	16	13	>60
F6	F	31	Yes	No	17	15	>60
M1	M	52	Yes	No	19	9	>60
F7	F	49	Yes	No	23	11	>60
F8	F	34	Yes	No	26	21	>60
F9	F	35	Yes	No	28	12	>60
F10	F	31	Yes	No	29	7	>60
F11	F	35	Yes	No	30	23	>60
F12	F	34	Yes	No	30	12	>60
F13	F	27	Yes	No	32	22	>60
F14	F	42	Yes	No	32	21	52.84
F15	F	51	No	No	34	31	>60
F16	F	22	Yes	No	34	15	>60
F17	F	29	Yes	No	35	16	>60
F18	F	41	Yes	No	37	27	>60
F19	F	31	Yes	No	45	20	>60
F20	F	20	Yes	No	52	42	>60
M2	M	53	Yes	Yes	57	41	> 60
F21	F	31	Yes	Yes	63	40	>60
F22	F	41	Yes	Yes	64	40	>60

Heme arginate treatment: Normosang®; 3 mg/Kg; every 2–3 weeks; PBG: porphobilinogen concentrations (nmol/mmol creatinine); ALA: aminolevulinic acid concentrations nmol/mmol creatinine). GFR: glomerular filtration rate (mls/min).

ISSN: 1750-1172